ADMA Biologics Inc vs ProShares Ultra Silver ETF — how do they compare? ADMA Biologics Inc trades at $9.92 (market cap $2.22B), while ProShares Ultra Silver ETF trades at $82.81. Which is the better fit depends on your goals.
| ADMA | AGQ | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.38 | $400.47 |
52-Week Low | $7.60 | $49.73 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
AGQ, the ProShares Ultra Silver ETF, trades at $83.06, up 1.44% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights its volatility, surging 9.39% on silver rallies but facing structural decay concerns due to 2x daily leverage. Financial ratios are unavailable as it is an ETF tracking silver futures.
Outlook is highly speculative, offering amplified silver exposure with significant risk. Opportunities exist if silver prices rise, but risks include leverage decay, volatility-driven losses, and silver market downturns. Investors should weigh aggressive gains against potential rapid declines.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →